| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent developments highlight Eli Lilly's success in product/service development, particularly with its weight-loss drug Zepbound and diabetes medication Mounjaro, which exemplify effective market strategy and innovation. The company's commitment to advancing its product pipeline, with promising research and innovative offerings, demonstrates potential for significant growth, especially in the expanding obesity treatment market. Furthermore, strong performance in clinical trials reinforces investor confidence in the efficacy and marketability of upcoming drugs. Eli Lilly's leadership in the weight-loss drug market positions it favorably for ongoing revenue growth. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 1 is bullish. The market sentiment at 2.2 is extremely bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 2.2, and the negative at 0 on 2025-11-24. The forces of Valuation Sentiment (5.3), Sentiment towards Fundamentals (5.1), Market Risk Appetite (1), Sector Price Trend (1), Stock Price Trend (1), Option Sentiment (0), and Price Level Sentiment (0) will drive up the price. The forces of and Price Level Sentiment (0) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | 0%(0.4%) | 1 | 0.25% | 2.2 | 5.1 | -1 | |||||||
| 2025-11-23 | 0%(0.4%) | 1 | 0.25% | 2 | 4.7 | -1 | |||||||
| 2025-11-22 | 1%(0.4%) | 1 | 0.25% | 2.1 | 4.7 | 7.5 | |||||||
| 2025-11-21 | 2%(0.3%) | 1 | 0.25% | 2.2 | 4.2 | 7.3 | |||||||
| 2025-11-20 | 0%(0%) | 1 | 0.25% | 1.2 | 3.8 | -1 | |||||||
| 2025-11-19 | 0%(0%) | 1 | 0.25% | 1.1 | 3.5 | 7 | |||||||
| 2025-11-18 | 0%(0%) | 1 | 0.25% | 0.9 | 2.4 | -1 | |||||||
| 2025-11-17 | 0%(0%) | 1 | 0.25% | 1.5 | 2.7 | 7 | |||||||
| 2025-11-16 | 0%(0%) | 1 | 0.25% | 1.6 | 3.1 | 4 | |||||||
| 2025-11-15 | 0%(0%) | 1 | 0.25% | 1.4 | 3.2 | 4 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-24 17:02:33 Eli Lilly's management strategy is examined, particularly in comparison to its competitors. |
| 2025-11-24 17:02:33 Burk Holdings' acquisition of Eli Lilly shares reflects interest in the company's performance. |
| 2025-11-24 17:02:33 Positive data from Phase 3 studies of Jaypirca indicates strong development in their product pipeline. |
| 2025-11-24 17:02:33 Eli Lilly's competitive standing against Novo Nordisk is analyzed, showcasing its execution abilities. |
| 2025-11-24 17:02:33 Articles discuss the stock performance of Eli Lilly, highlighting gains and investment activity. |